By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
BreakingHealth

European health agency finds no evidence of Andes hantavirus mutation

Last updated: May 13, 2026 11:52 pm
Haris Ali
Share
SHARE

The European Centre for Disease Prevention and Control (ECDC) has confirmed that the Andes strain of hantavirus shows no signs of genetic mutation capable of driving human-to-human transmission. The assessment follows intensified monitoring of the virus, which is primarily transmitted to humans through contact with the excreta of infected rodents.

Public health officials have been on alert due to the high mortality rate associated with the Andes strain, particularly in South America. While the virus can cause Hantavirus Pulmonary Syndrome (HPS)—a severe respiratory illness—it has historically remained a zoonotic disease. The ECDC’s latest technical report serves to dampen speculation that the virus is evolving to spread easily between people.

“Current data confirms the transmission route remains consistent with historical patterns,” the agency noted in its brief. It emphasized that sporadic cases reported in endemic regions do not indicate a shift in the pathogen’s biological behavior or environmental stability.

The Andes virus remains a localized threat, largely contained within specific rodent populations in Argentina and Chile. Unlike other viruses that trigger global concern through rapid adaptation, this strain depends entirely on direct contact with contaminated environments.

Public health experts maintain that the primary defense remains ecological management. Preventing contact with rodent nests and maintaining hygiene in rural areas are the only proven methods to curb infection.

Despite the ECDC’s findings, medical teams in the affected regions continue to monitor patients closely. The focus remains on early clinical intervention, as the window for effective treatment for HPS is narrow. For now, the threat remains contained to its traditional biological boundaries, with no evidence of the viral evolution that would spark a wider public health crisis.

Share This Article
Email Copy Link Print
Previous Article Meghan Markle Launches Lifestyle Brand as Princess Kate Heads to Italy Meghan Markle Launches Lifestyle Brand as Princess Kate Heads to Italy
Next Article Seven militants killed, five soldiers martyred in Balochistan gun battle Seven militants killed, five soldiers martyred in Balochistan gun battle
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Record-Breaking Heat Grips U.S. Ahead of July 4 Holiday
Record-Breaking Heat Grips U.S. Ahead of July 4 Holiday
Climate and Weather Headline
July 1, 2026
U.S. and Iran to Meet with Mediators in Qatar
U.S. and Iran to Meet with Mediators in Qatar
Headline Politics
July 1, 2026
Indus Commissioner: India remains silent on Chenab water flow concerns
Indus Commissioner: India remains silent on Chenab water flow concerns
Breaking
July 1, 2026
Eleven-year-old dies of rabies after bat roosts on his mouth
Eleven-year-old dies of rabies after bat roosts on his mouth
Headline Health
July 1, 2026
Interior Minister Mohsin Naqvi’s Saudi Visit Focuses on Security Cooperation
Interior Minister Mohsin Naqvi’s Saudi Visit Focuses on Security Cooperation
Headline Politics
July 1, 2026
PPP and JUI-F Form Alliance for AJK Elections
PPP and JUI-F Form Alliance for AJK Elections
Headline Politics
July 1, 2026

You Might Also Like

Health

Surgery Performed Under Mobile Phone Light at Services Hospital, Maryam Nawaz Takes Notice and Seeks Report

By
Neha Ashraf
N.I.H. Funding Slows Further in Trump’s Second Year, Delaying New Research
Health

N.I.H. Funding Slows Further in Trump’s Second Year, Delaying New Research

By
Misbah Jogyat
Health

Breast Cancer Awareness Campaign Held in Karachi, Health Minister Emphasizes Timely Diagnosis

By
Neha Ashraf
WASHINGTON: UnitedHealth has warned that the Trump administration’s planned Medicare obesity-drug pilot faces “notable challenges,” casting doubt over how smoothly the program can move ahead if major insurers stay cautious. Recent market reporting said the model depends heavily on participation from Medicare drug plans that cover most Part D enrollees, which makes the stance of large insurers especially important. The concern centers on a broader CMS effort to expand access to GLP-1 weight-loss medicines for seniors. Under CMS’s published framework, the longer-term BALANCE Model would begin in Medicare Part D in January 2027, while a temporary Medicare GLP-1 Bridge is designed to start earlier and give eligible beneficiaries short-term access before that main model begins. What makes this a little more complicated is that the short-term bridge and the longer pilot are not the same thing. CMS says the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, meaning Part D sponsors are not directly involved in that bridge arrangement. In other words, insurer participation is a much bigger issue for the 2027 BALANCE rollout than for the bridge itself. That distinction matters because investors and drugmakers are watching this closely. Reports said shares of obesity-drug makers fell after UnitedHealth’s comments, largely because Medicare coverage is seen as a huge growth opportunity for drugs such as Wegovy and Zepbound. If major insurers hesitate, the program could struggle to achieve the scale CMS appears to want. There is already some evidence of resistance. MarketWatch reported that CVS Health has opted out, while UnitedHealth is still evaluating the structure and discussing possible changes with Medicare officials. That does not mean the program is dead, not yet anyway, but it does suggest the administration may need to revise the design or sweeten the terms if it wants broader insurer buy-in. The bigger backdrop here is cost. Medicare has long been wary of broad obesity-drug coverage because GLP-1 therapies are expensive and potentially involve very large patient populations. Earlier policy debates around these drugs were shaped by concerns that wide coverage could drive up federal spending sharply, even as supporters argued the medicines could reduce longer-term health costs tied to obesity. So the headline problem for CMS is pretty straightforward: it has created a short-term bridge that can move without direct Part D plan involvement, but the more ambitious long-term Medicare model still appears to need insurers on board. UnitedHealth’s warning does not shut the door, but it does signal that one of the industry’s biggest players thinks the current setup may not be ready for easy launch.
HeadlineHealth

UnitedHealth raises red flags over Medicare obesity-drug pilot

By
Mabruka Khan
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?